This week, Jonathan Royce assumed the role of chief executive officer of Bio-Works Sweden (BIOWKS.ST). He comes most recently from a role as Director of Instruments at Vironova AB and has a background in senior leadership roles within large-scale suppliers to the biopharmaceutical market including Millipore (now Merck-Millipore) and GE Healthcare Life Sciences (now Cytiva).
“With deep industry experience and a proven track record of performance, Jonathan is the right leader to lead Bio-Works into the future as an innovator in downstream purification,” said Peter Ehrenheim, chairman of the Bio-Works Board of Directors. “We’re confident Jonathan will take Bio-Works forward with a focus on furthering the company’s commercial success.”
“We also want to thank Mats Johnson for his leadership as CEO during the past three years. Mats has built a strong foundation upon which Bio-Works can continue to grow,” concluded Ehrenheim.
Royce, 43, has served in various senior leadership roles within several large-scale suppliers to the biopharmaceutical market including Millipore (now Merck-Millipore) and GE Healthcare Life Sciences (now Cytiva). During his 11-year tenure at GE, he led teams in global marketing of the bioprocessing portfolio, and global product management of the chromatography resins business. He has most recently held the role of Director of Instruments at Vironova AB, a Swedish biotech company focused on the viral vector market.
“I’m honored to lead the talented people of Bio-Works. Working together, we will strengthen our culture, continue to innovate and build trust with customers and collaborators,” said Royce. “With the strength of our team and product portfolio, I’m confident in the future of Bio-Works.”
For more information please visit Bio-Works’ homepage, www.bio-works.com or contact Jonathan Royce, CEO, e-mail: jonathan.royce@bio-works.com, telephone: +46(0) 70-1434143.
Jonathan Royce, CEO
Bio-Works designs, develops, manufactures and supplies innovative leading-edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. Bio-Works’ agarose based high performance products are used for purification in the life science research phases as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally with our own organization and via distributors. The Bio-Works’ headquarter with R&D and manufacturing is located in Uppsala Business Park in Uppsala, Sweden and the company processes and a Quality Management System follows the standards of ISO 9001:2015. The company’s share is listed on Nasdaq First North. FNCA Sweden AB, +46 (0) 8-528 00 399, info@fnca.se, is appointed Certified Adviser.
